12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GLV-1h68: Phase I started

Genelux said investigators at the Memorial Sloan Kettering Cancer Center began an open-label, dose-escalation, U.S. Phase I trial to evaluate GL-ONC1 administered intrapleurally in up to 54 patients with cancers including mesothelioma and...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >